Literature DB >> 14992436

Differences in dihydropyrimidine dehydrogenase activities between gastric and colorectal cancer.

Bunzo Nakata1, Kazuya Muguruma, Shigehito Yamagata, Kiyotaka Yukimoto, Kiyoshi Maeda, Yukio Nishiguchi, Masaichi Ohira, Yasuyuki Kato, Kosei Hirakawa.   

Abstract

We studied the relation between clinicopathological factors and dihydropyrimidine dehydrogenase (DPD) activity in gastric and colorectal carcinomas. Specimens obtained by surgery from 27 gastric and 17 colorectal carcinomas and their normal mucosa were examined. The levels of DPD activity in the gastric carcinomas and their normal mucosa were significantly higher than those in colorectal carcinomas and their normal counterparts, respectively (both P's < 0.0001). The gastric carcinomas had significantly higher DPD activities than their normal mucosa (P = 0.028), but the colorectal carcinomas did not. Among the clinicopathological factors, which included invasion/metastatic status and staging, the only effect was that of the histological differences of gastric cancer on DPD activity. That is, the level of DPD activity of the histologically undifferentiated gastric carcinoma was significantly higher than that of the differentiated type. No prognostic predictive values of DPD were recognized in either gastric and colorectal cancer. In conclusion, the higher DPD activity in gastric cancer than colorectal cancer may be due to the higher DPD activity in the background mucosa of origin, and the higher population of undifferentiated type of histological classification, compared to the colorectal counterparts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14992436     DOI: 10.1023/b:ddas.0000011603.40133.f9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

1.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

2.  Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma.

Authors:  Hiroaki Nozawa; Hajime Tsukui; Koichiro Nishida; Kazuhiro Yakumaru; Hirokazu Nagawa; Takayoshi Sekikawa
Journal:  Cancer Chemother Pharmacol       Date:  2002-01-29       Impact factor: 3.333

3.  Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer.

Authors:  H Uetake; W Ichikawa; T Takechi; M Fukushima; Z Nihei; K Sugihara
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

4.  Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography.

Authors:  J P Sommadossi; D A Gewirtz; R B Diasio; C Aubert; J P Cano; I D Goldman
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

5.  Adjuvant therapy for colon cancer.

Authors:  J S Macdonald
Journal:  CA Cancer J Clin       Date:  1997 Jul-Aug       Impact factor: 508.702

Review 6.  Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.

Authors:  Y M Rustum; A Harstrick; S Cao; U Vanhoefer; M B Yin; H Wilke; S Seeber
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

7.  Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer.

Authors:  Y Ishikawa; T Kubota; Y Otani; M Watanabe; T Teramoto; K Kumai; T Takechi; H Okabe; M Fukushima; M Kitajima
Journal:  Anticancer Res       Date:  1999 Nov-Dec       Impact factor: 2.480

Review 8.  Review of adjuvant chemotherapy for gastric cancer.

Authors:  T Nakajima
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

Review 9.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

10.  Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.

Authors:  Y Ishikawa; T Kubota; Y Otani; M Watanabe; T Teramoto; K Kumai; T Takechi; H Okabe; M Fukushima; M Kitajima
Journal:  Jpn J Cancer Res       Date:  2000-01
View more
  2 in total

1.  Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.

Authors:  Wenqi Bai; Yueqin Wu; Ping Zhang; Yanfeng Xi
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.

Authors:  J-S Kim; M-A Kim; T M Kim; S-H Lee; D-W Kim; S-A Im; T-Y Kim; W H Kim; H-K Yang; D S Heo; Y-J Bang; K-U Lee; K-J Choe; N K Kim
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.